Health Care • Medical/Dental Instruments
$293.30 ▲ +7.30
(+2.55%)
MKT CAP: $2.27B • VOL: 107.6K
52W L $174 52W H $339
UFPT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $602.8M | $504.4M | $400.1M |
| YoY Revenue Growth % | +19.5% | +26.1% | — |
| Gross Profit | $170.4M | $146.7M | — |
| Gross Margin % | 28.3% | 29.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $92.3M | $80.9M | $57.7M |
| Operating Margin % | 15.3% | 16.0% | 14.4% |
| Net Income (GAAP) | $68.3M | $59.0M | $44.9M |
| EBITDA (Normalized) | — | $88.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $91.9M | $66.6M | $41.3M |
| Capital Expenditures (CapEx) | — | $9.7M | — |
| Free Cash Flow (FCF) | $91.9M | $56.9M | $41.3M |
| FCF Margin % | 15.2% | 11.3% | 10.3% |
| Return on Invested Capital (ROIC %) | 13.9% | 12.6% | — |
| Cash & Short-Term Equivalents | $20.3M | $13.4M | — |
| Total Debt (Short + Long Term) | $123.0M | $176.9M | — |
| Total Stockholders' Equity | $423.9M | $342.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UFPT.